genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Allogene Therapeutics
Drug Discovery
$600M+ Credit Firm Targets Life-Sci Companies in Later Stages
Cancer
ElevateBio and Boston Children’s Reveal New Company for Manufacturing Allogenic Immune Therapies
Cancer
FDA Places Clinical Hold on Allogene CAR-T Cancer Trials
Cancer
Allogene, Notch Partner to Develop iPSC-Derived Blood Cancer Therapies
A-Lists
Top 10 Immuno-Oncology Collaborations
News
VC Investment Jumps 51% Year-over-Year During Q3
Cancer
Pfizer Hands UCART19, Allogenic CAR-T Portfolio Rights to $300M Startup
Scroll Up
Scroll Up
